View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, June 23 (HealthDay News) -- The U.S. Food and Drug Administration has authorized a new test that uses molecular biology techniques to diagnose 2009 H1N1 influenza virus infection in humans.
The "CDC Influenza 2009 A (H1N1)pdm Real-Time RT-PCR Panel (IVD)," developed by the U.S. Centers for Disease Control and Prevention over the past several months, can isolate and detect viral genetic material from sputum samples taken from a patient's upper or lower respiratory tract in a doctor's office or hospital. The H1N1 virus genetic material is amplified to generate a fluorescent signal which is detected with the Applied Biosystems 7500 Fast DX Real-Time PCR Instrument. The test can produce a result within four hours.
The new test replaces a former test developed with limited H1N1 specimens and authorized by the FDA for emergency use in April 2009. With the large amounts of genetic material gathered since the 2009 pandemic, the new test has been improved to detect 2009 H1N1 virus with sensitivity and specificity greater than 96 percent using upper respiratory specimens. The test is expected to be available to CDC-qualified laboratories soon.
"This clearance represents several months of close collaboration between the FDA and the CDC," Jeffrey Shuren, M.D., director of the FDA's Center for Devices and Radiological Health, said in a statement. "This test is the second diagnostic cleared in recent weeks by the FDA for the 2009 H1N1 influenza virus."
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top